Literature DB >> 2926872

Critical evaluation of treatment of staghorn calculi by percutaneous nephrolithotomy and extracorporeal shock wave lithotripsy.

H Schulze1, L Hertle, A Kutta, J Graff, T Senge.   

Abstract

The combined use of percutaneous nephrolithotomy and extracorporeal shock wave lithotripsy in patients with staghorn calculi has become an established treatment regimen. We evaluated the results of 90 staghorn calculi-bearing kidneys treated with such combination therapy after a mean follow-up of approximately 2 years. A total of 69 kidneys (76.7 per cent) became free of stones at some point after treatment. However, due to stone recurrence this number decreased to 55 kidneys (61.1 per cent) at the end of follow-up. Patients who had undergone a previous open operation on the stone-bearing kidney showed less favorable results than the over-all group. When our results were compared to reported data on open surgery or percutaneous nephrolithotomy alone even better results may have been obtained by such treatment modalities. However, our data indicate that percutaneous stone debulking combined with further destruction of residual stone fragments by shock wave lithotripsy certainly is less invasive than an open operation and provides an alternative to percutaneous treatment alone, which can yield comparable results.

Entities:  

Mesh:

Year:  1989        PMID: 2926872     DOI: 10.1016/s0022-5347(17)41020-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Totally tubeless percutaneous nephrolithotomy: a prospective randomized controlled study.

Authors:  Chien-Hsing Chang; Chung-Jing Wang; Shi-Wei Huang
Journal:  Urol Res       Date:  2011-02-18

Review 2.  The recurrence rate of stones following ESWL.

Authors:  K U Köhrmann; J Rassweiler; P Alken
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

3.  Open stone surgery: is it still a preferable procedure in the management of staghorn calculi?

Authors:  A A Esen; Z Kirkali; C Güler
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.